| 6.7 -0.16 (-2.33%) | 05-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.2 |
1-year : | 8.87 |
| Resists | First : | 7.02 |
Second : | 7.59 |
| Pivot price | 6.8 |
|||
| Supports | First : | 6.09 |
Second : | 5.07 |
| MAs | MA(5) : | 6.85 |
MA(20) : | 6.82 |
| MA(100) : | 7.26 |
MA(250) : | 8.06 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 50 |
D(3) : | 54.8 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 12.05 | Low : | 5.4 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ADXN ] has closed above bottom band by 38.0%. Bollinger Bands are 27.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.72 - 6.75 | 6.75 - 6.78 |
| Low: | 6.61 - 6.65 | 6.65 - 6.69 |
| Close: | 6.64 - 6.71 | 6.71 - 6.76 |
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Wed, 06 May 2026
Technical Reactions to ADXN Trends in Macro Strategies - Stock Traders Daily
Thu, 30 Apr 2026
Addex Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Thu, 30 Apr 2026
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update - marketscreener.com
Thu, 30 Apr 2026
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update - The Manila Times
Thu, 30 Apr 2026
Addex Therapeutics H2 2025 Earnings Call Transcript - MarketBeat
Thu, 30 Apr 2026
Addex Therapeutics (NASDAQ: ADXN) swings to 2025 loss, cash at CHF 1.6m - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 9.272e+007 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.46e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 403.5 % |
| Return on Equity (ttm) | -15.9 % |
| Qtrly Rev. Growth | 158540 % |
| Gross Profit (p.s.) | -8.03 |
| Sales Per Share | -38.96 |
| EBITDA (p.s.) | -281096 |
| Qtrly Earnings Growth | -9.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.18 |
| Price to Cash Flow | 1.61 |
| Dividend | 0 |
| Forward Dividend | 7260 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|